摘要
目的研究窄谱中波紫外线、奥洛他定联合糠酸莫米松对局限性神经性皮炎患者炎症水平及神经营养因子的影响。方法选取周口市中医院2021年9月至2023年9月期间89例局限性神经性皮炎患者随机分组,对照组44例给予奥洛他定联合糠酸莫米松治疗,观察组45例在对照组基础上联合窄谱中波紫外线治疗。对比两组患者临床疗效,炎症水平,神经营养因子水平和不良反应。结果观察组治疗总有效率高于对照组(P<0.05)。治疗后,观察组肿瘤坏死因子-α水平低于对照组,干扰素-γ、白细胞介素-2水平高于对照组(P<0.05);观察组脑源性神经营养因子、胶质细胞脑源性神经营养因子水平均高于对照组(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论窄谱中波紫外线、奥洛他定联合糠酸莫米松能够有效降低局限性神经性皮炎患者炎症水平,提高神经营养因子水平,加速皮肤修复,安全性高。
Objective To study the effects of narrow-spectrum UVB,olopatadine combined with mometasone furoate on inflammation levels and neurotrophic factors in patients with localized neurodermatitis.Methods A total of 89 patients with localized neurodermatitis were randomly assigned from September 2021 to September 2023 in Zhoukou Hospital of Traditional Chinese Medicine.44 patients in the control group were given olopatadine combined with mometasone furoate,and 45 patients in the observation group were combined with narrow-spectrum UVB treatment on the basis of the control group.The clinical efficacy,levels of inflammation,levels of neurotrophin and adverse reactions were compared between the two groups.Results The total effective rate of observation group was higher than that of control group(P<0.05).After treatment,the levels of tumor necrosis factor-αin observation group were lower than those in control group,and the levels of interferon-γand interleukin-2 were higher than those in control group(P<0.05);the levels of brain-derived neurotrophic factor and glial brain-derived neurotrophic factor in observation group were higher than those in control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Narrow-spectrum UVB and olopatadine combined with mometasone furoate can effectively reduce the level of inflammation in patients with localized neurodermatitis,improve the level of neurotrophic factors,accelerate skin repair,and have high safety.
作者
张晓艳
路斌
ZHANG Xiaoyan;LU Bin(Zhoukou Hospital of Traditional Chinese Medicine,Zhoukou Henan 466099,China)
出处
《药品评价》
CAS
2024年第4期507-510,共4页
Drug Evaluation